Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge

Oliveria, John Paul; El-Gammal, Amani; Yee, Michelle; Obminski, Caitlin; Scime, Tara; Watson, Richard M.; Howie, Karen; O'Byrne, Paul M.; Sehmi, Roma; Gauvreau, Gail M.

doi:10.1016/j.jaci.2017.11.013

Cited by 21 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase of CD27 + TBs in asthma patients was not due to the increase of total TBs (Figure B) or CD27 + total B cells (data not shown). In contrast to CD27 + and CD10 + TBs, OCS treatment resulted in a significant decrease of CD5 + TBs in asthma patients which might have an important relevance in the pathogenesis of human asthma as well as other inflammatory diseases . The lack of changes in frequency of total TBs, CD24 high CD27 + B cells and B1 cells in allergic asthma patients recruited in this study contrasts with previous findings in rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and allergic rhinitis .…”

Section: Discussioncontrasting

confidence: 99%

“…Our second major observation is that OCS treatment results in decreases of IL‐10 expression by CD27 + TBs, CD24 high CD27 + B cells and B1 cells. It is thus worth to re‐examine the previous published data on IL‐10 expression by Bregs based on patient treatment regimens especially oral corticosteroid. Due to the limited numbers of cells collected from patients, we used IL‐10 expression as a functional marker of Breg subsets in this study.…”

Section: Discussionmentioning

confidence: 99%

“…lished data on IL-10 expression by Bregs 13,20,26,29,41,43,44 based on patient treatment regimens especially oral corticosteroid. Due to the limited numbers of cells collected from patients, we used IL-10 expression as a functional marker of Breg subsets in this study.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Phenotypic and functional alterations of regulatory B cell subsets in adult allergic asthma patients

Wiest

Upchurch

Hasan

et al. 2019

Clin Experimental Allergy

View full text Add to dashboard Cite

Background IL‐10‐producing regulatory B cells (Bregs) are widely ascribed immune regulatory functions. However, Breg subsets in human asthma have not been fully investigated. Objective We studied Breg subsets in adult allergic asthma patients by assessing two major parameters, frequency and IL‐10 expression. We then investigated factors that affect these two parameters in patients. Methods Peripheral blood mononuclear cells (PBMCs) of adult allergic asthma patients (N = 26) and non‐asthmatic controls (N = 28) were used to assess the frequency of five subsets of transitional B cells (TBs), three subsets of CD24highCD27+ B cells and B1 cells. In addition to clinical data, IL‐10 expression by individual Breg subsets was assessed by flow cytometry. Results Asthma patients had decreases of CD5+ and CD1d+CD5+, but an increase of CD27+ TBs which was significant in patients with moderate asthma (60 < FEV1 < 80). Regardless of asthma severity, there was no significant alteration in the frequencies of 6 other Breg subsets tested. However, we found that oral corticosteroid (OCS) significantly affected the frequency of Bregs in Breg subset‐specific manners. OCS decreased CD5+ and CD1d+CD5+ TBs, but increased CD27+ TBs and CD10+CD24highCD27+ cells. Furthermore, OCS decreased IL‐10 expression by CD27+ TBs, all 3 CD24highCD27+ B cell subsets (CD5+, CD10+ and CD1d+) and B1 cells. OCS‐mediated inhibition of IL‐10 expression was not observed in the other Breg subsets tested. Conclusion & Clinical Relevance Alterations in the frequency of Bregs and their ability to express IL‐10 are Breg subset‐specific. OCS treatment significantly affects the frequency as well as their ability to express IL‐10 in Breg subset‐specific manners.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Phenotypic and functional alterations of regulatory B cell subsets in adult allergic asthma patients

Wiest

Upchurch

Hasan

et al. 2019

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Allergen-specific immunotherapy is a promising approach to reduce or remove allergic symptoms by inducing tolerance. 1 As an alternative to current allergy vaccines derived from extracts of natural allergens, recombinant vaccines offer the opportunity for de novo antigen design, 2 with enhanced targeting to antigen-presenting cells (APCs) and potentially increased ability to induce tolerance. 3,4 Using the type 1 allergen Bet v 1 as our model antigen, we evaluated the effects of combining a nonglycosylated antigen to a glycomodule 5 to target the APC-expressed family of C-type lectin receptors (CLRs).…”

Section: Genetically Engineered Cell Factories Produce Glycoengineerementioning

confidence: 99%

Biomatrix for upper and lower airway biomarkers in patients with allergic asthma

Zissler

Ulrich

Jakwerth

et al. 2018

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Although many biomarkers have been proposed for asthma monitoring, only the noninvasively accessible fraction of exhaled nitric oxide has been established into clinical routine, whereas implementation into guidelines is pending. 1 The upper and lower airways are considered a morphologic and functional unit and share air transport, physical barrier, mucociliary clearance, and immune interface as common features. 2 Furthermore, not only do allergic rhinitis and asthma share mechanisms of allergic inflammation, but also, transition of allergic rhinitis into asthma can represent a steady continuum depending on endotype. Therefore nasal secretions

show abstract

“…12 Numbers of Breg cells were decreased in the circulation of asthmatic patients. 11 B cells in draining lymph nodes skewed developing T H 0 cells into T H 2 and T H 17 cells. 10 During an airway secondary immune response, B cells induced T H 2 cell proliferation, which associated with eosinophilic asthma.…”

Section: Biomarkers and Mechanismsmentioning

confidence: 99%

Advances in asthma in 2017: Mechanisms, biologics, and genetics

Grayson

Feldman

Prince

et al. 2018

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

This review summarizes some of the most significant advances in asthma research over the past year. We first focus on novel discoveries in the mechanism of asthma development and exacerbation. This is followed by a discussion of potential new biomarkers, including the use of radiographic markers of disease. Several new biologics have become available to the clinician in the past year, and we summarize these advances and how they can influence the clinical delivery of asthma care. After this, important findings in the genetics of asthma and heterogeneity in phenotypes of the disease are explored, as is the role the environment plays in shaping the development and exacerbation of asthma. Finally, we conclude with a discussion of advances in health literacy and how they will affect asthma care.

show abstract

Changes in regulatory B-cell levels in bone marrow, blood, and sputum of patients with asthma following inhaled allergen challenge

Cited by 21 publications

References 19 publications

Phenotypic and functional alterations of regulatory B cell subsets in adult allergic asthma patients

Phenotypic and functional alterations of regulatory B cell subsets in adult allergic asthma patients

Biomatrix for upper and lower airway biomarkers in patients with allergic asthma

Advances in asthma in 2017: Mechanisms, biologics, and genetics

Contact Info

Product

Resources

About